{"altmetric_id":10205093,"counts":{"readers":{"mendeley":3,"citeulike":0,"connotea":0},"total":{"posts_count":2},"news":{"unique_users_count":1,"unique_users":["md_magazine"],"posts_count":1},"twitter":{"unique_users_count":1,"unique_users":["TZiemssen"],"posts_count":1}},"citation":{"altmetric_jid":"54e7893c2a83ee46118b45a2","authors":["Lina Hassoun","Judith Eisele","Katja Thomas","Tjalf Ziemssen"],"doi":"10.1186\/s40893-016-0011-1","first_seen_on":"2016-08-02T10:32:59+00:00","issns":["2056-6115"],"issue":"1","journal":"Multiple Sclerosis and Demyelinating Disorders","last_mentioned_on":1470323794,"links":["https:\/\/msddjournal.biomedcentral.com\/articles\/10.1186\/s40893-016-0011-1","http:\/\/dx.doi.org\/10.1186\/s40893-016-0011-1"],"pdf_url":"http:\/\/msddjournal.biomedcentral.com\/track\/pdf\/10.1186\/s40893-016-0011-1?site=msddjournal.biomedcentral.com","pubdate":"2016-08-02T00:00:00+00:00","publisher":"BioMed Central","publisher_subjects":[{"name":"Medicine & Public Health","scheme":"springer"},{"name":"Neurology","scheme":"springer"},{"name":"Rehabilitation Medicine","scheme":"springer"}],"startpage":"1","title":"Hands on Alemtuzumab-experience from clinical practice: whom and how to treat","type":"article","volume":"1","mendeley_url":"http:\/\/www.mendeley.com\/research\/hands-alemtuzumabexperience-clinical-practice-whom-treat"},"altmetric_score":{"score":10,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":10},"context_for_score":{"all":{"total_number_of_other_articles":8166192,"mean":6.9129712202356,"rank":819399,"this_scored_higher_than_pct":89,"this_scored_higher_than":7314198,"rank_type":"exact","sample_size":8166192,"percentile":89},"similar_age_3m":{"total_number_of_other_articles":257829,"mean":11.998069658842,"rank":38436,"this_scored_higher_than_pct":84,"this_scored_higher_than":218505,"rank_type":"exact","sample_size":257829,"percentile":84},"this_journal":{"total_number_of_other_articles":9,"mean":3.335,"rank":2,"this_scored_higher_than_pct":77,"this_scored_higher_than":7,"rank_type":"exact","sample_size":9,"percentile":77},"similar_age_this_journal_3m":{"total_number_of_other_articles":4,"mean":4.81,"rank":2,"this_scored_higher_than_pct":50,"this_scored_higher_than":2,"rank_type":"exact","sample_size":4,"percentile":50}}},"demographics":{"poster_types":{"member_of_the_public":1},"users":{"twitter":{"cohorts":{"Members of the public":1}},"mendeley":{"by_status":{"Student  > Doctoral Student":1,"Other":2},"by_discipline":{"Medicine and Dentistry":2,"Neuroscience":1}}},"geo":{"twitter":{"DE":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/TZiemssen\/statuses\/760423066610573313","license":"gnip","citation_ids":[10205093],"posted_on":"2016-08-02T10:32:41+00:00","author":{"name":"Tjalf Ziemssen","image":"https:\/\/pbs.twimg.com\/profile_images\/1144733282\/TZiemssen_normal.JPG","description":"Neurologist","id_on_source":"TZiemssen","tweeter_id":"191434214","geo":{"lt":51.05089,"ln":13.73832,"country":"DE"},"followers":110},"tweet_id":"760423066610573313"}],"news":[{"title":"Multiple Sclerosis: Who, and How, to Treat with Alemtuzumab","url":"http:\/\/ct.moreover.com\/?a=27502539393&p=1pl&v=1&x=JuBC1lrfWHXzskoTqzY-ww","license":"public","citation_ids":[10205093,10205093],"posted_on":"2016-08-04T15:16:34+00:00","summary":"Researchers in Germany recently reviewed the use of alemtuzumab, a monoclonal antibody used to treat relapsing remitting multiple sclerosis (RRMS), over the last two years and identified important first steps in patient selection, preparation\u2026","author":{"name":"MD Magazine","url":"http:\/\/www.hcplive.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/706\/normal\/Screen_Shot_2016-01-26_at_15.06.24.png?1453820807"}}]}}